A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease
Latest Information Update: 15 Jul 2024
Price :
$35 *
At a glance
- Drugs Amlodipine/olmesartan-medoxomil/rosuvastatin (Primary) ; Olmesartan medoxomil/amlodipine
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 19 May 2022 Status changed from recruiting to completed.
- 14 Oct 2019 New trial record